IL1B and juvenile idiopathic arthritis: In JIA patients, serum concentrations of IL-1β remain poorly detectable despite the demonstration of an IL-1β transcriptional signature in PBMCs and the well-established therapeutic efficiency of IL-1β-blocking antibody canakinumab or recombinant IL-1 receptor antagonist, anakinra (1, 48).